Back to results
US 2022/0280519 A1Published application
Combinations of agents to treat hematological malignancies
AssigneeOregon Health & Science University
InventorsJeffrey Tyner, Stephen Kurtz, Brian Druker, Elie Traer, Christopher Eide, Motomi Mori, Andrew Kaempf
Life of this patent
Estimating the term…
Abstract
Methods of treating acute myeloid leukemia, chronic lymphocytic leukemia and myeloproliferative neoplasms that involve the administration of combinations of small molecule compounds are disclosed.
Claims11
A method of identifying a subject with chronic lymphoblastic leukemia that is responsive to combined therapy with (i) palbociclib and (ii) venetoclax, the method comprising:
- obtaining a biological sample from a human patient with chronic lymphoblastic leukemia;
- detecting whether there is a chromosome 13q deletion in the biological sample by contacting the sample with (i) a labelled probe that bind to chromosome 13q or (ii) a dye that stains chromosomes for microscopy analysis;
- and
- detecting binding between the probes or the dye and chromosome 13q,
- wherein the subject is identified as having chronic lymphoblastic leukemia that is responsive to combined therapy with (i) palbociclib and (ii) venetoclax if a chromosome 13q deletion is detected in the sample.
2 more elements
A method of:
- (a) identifying a subject with chronic lymphoblastic leukemia that is responsive to combined therapy with (i) palbociclib and (ii) venetoclax;
- and (b) treating the subject,
- the method comprising:
- obtaining a biological sample from a living human patient with chronic lymphoblastic leukemia;
- detecting whether a chromosome 13q deletion is present in the biological sample;
- identifying the subject as having chronic lymphoblastic leukemia that is responsive to combined therapy with (i) palbociclib and (ii) venetoclax when a chromosome 13q deletion is detected in the biological sample;
- and
- administering an effective amount of (i) palbociclib and (ii) venetoclax to the subject.
5 more elements
Dependencies are inferred from the claim text.